机构：[1]State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.[2]College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.[3]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[4]University of Chinese Academy of Sciences, Beijing 100049, China.[5]Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.[6]Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
The implementation of COVID-19 policy and the rapid development of SARS-CoV-2 vaccines in the early pandemic significantly contained numerous outbreaks and reduced the severity and mortality of COVID-19. However, the population immunity induced by existing vaccines was insufficient to prevent SARS-CoV-2 outbreaks. The host immunity induced by the wide spread of Omicron variants and its influence on emerging SARS-CoV-2 variants are attracting broad attention. In this study, a clinical data analysis of the patients indicated that pre-vaccination reduced inflammatory responses and mitigated the severity of COVID-19 cases caused by natural infection with Omicron BA.5.2. The analysis of adaptive immune responses indicated that natural infection with BA.5.2 induced robust and broad immune responses, including both humoral and T cell-mediated immune responses (IFN-γ) against highly conserved viral antigens, and provided cross-reactive neutralization against various viral variants. Collectively, we report that the natural infection with Omicron BA.5.2 induced broad cross-reactive immunity against SARS-CoV-2 variants, which suggests that the development of a live attenuated SARS-CoV-2 vaccine with desired safety, high efficacy, broad spectrum, and long-term immune persistence is feasible. Therefore, we suggest that herd immunity, achieved through vaccination with attenuated vaccines, combined with booster doses of existing vaccines and antiviral therapy for people with high viral loads, may contribute to the eradication of this virus.
基金：
This research was supported by the National Key R&D Program of China (grant no.
2024YFA0920000), Shenzhen Medical Research Fund (grant no. B2303001), National Natural Science
Foundation of China (grant no. 82273837), and Shenzhen Science and Technology Program (grant no.
JCYJ20220818101405011).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|2 区生物学
小类|3 区微生物学
最新[2025]版：
大类|2 区生物学
小类|3 区微生物学
第一作者：
第一作者机构：[1]State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.[2]College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.
共同第一作者：
通讯作者：
通讯机构：[1]State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.[4]University of Chinese Academy of Sciences, Beijing 100049, China.
推荐引用方式(GB/T 7714)：
Li Le,Feng Tang,Shen Quan,et al.Natural Infection of Omicron BA.5.2 in Patients Provides Broad Immune Responses Against SARS-CoV-2[J].Microorganisms.2025,13(4):doi:10.3390/microorganisms13040746.
APA：
Li Le,Feng Tang,Shen Quan,Shi Xiaoshan,Wei Zhigong...&Si Longlong.(2025).Natural Infection of Omicron BA.5.2 in Patients Provides Broad Immune Responses Against SARS-CoV-2.Microorganisms,13,(4)
MLA：
Li Le,et al."Natural Infection of Omicron BA.5.2 in Patients Provides Broad Immune Responses Against SARS-CoV-2".Microorganisms 13..4(2025)
